Unigene Q2 revenue dips
Unigene’s net loss was $8.44m, or $0.09 loss per diluted share, compared to net loss of $3.64m, or $0.04 loss per diluted share, for the same period in
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.